NCT03430921 is a NA clinical trial of Enlighten™ Laser and a MLA Attachment in Scarring, sponsored by Cutera Inc..

Who is sponsoring NCT03430921?

NCT03430921 is sponsored by Cutera Inc..

What drugs are being tested in NCT03430921?

Interventions in NCT03430921: Enlighten™ Laser and a MLA Attachment.

What condition does NCT03430921 study?

NCT03430921 studies Scarring, Acne.

Is NCT03430921 still recruiting?

NCT03430921 is currently completed. Last updated 26 September 2023.

Are results published for NCT03430921?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-26 · How we verify

NCT03430921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment

Completed NA Results posted Last updated 26 September 2023

What this trial tests

NA trial testing Enlighten™ Laser and a MLA Attachment in Scarring in 4 participants. Completed in 30 May 2018.

Timeline

15 August 2017

Primary endpoint
30 May 2018

30 May 2018

Quick facts

Lead sponsor	Cutera Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	15 August 2017
Primary completion	30 May 2018
Estimated completion	30 May 2018
Sites	1 location across United States

Drugs / interventions tested

Enlighten™ Laser and a MLA Attachment

Conditions studied

Scarring — all drugs for Scarring →
Acne — all drugs for Acne →

Sponsor

Cutera Inc.

Who can join

Adults 18 to 65, any sex, with Scarring or Acne. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Acne Scarring Improvement Primary · Baseline, and at 12 weeks post final treatment (up to 30 weeks)

An improvement in Acne Scarring of at least one point on the Acne Scar Assessment Scale (ASAS):(1=clear scarring, 2=Very Mild scarring, 3=Mild scarring, 4=Moderate scarring or 5=Severe scarring) at the 12 weeks post final treatment

Baseline Acne Scar Assessment Scale Score

Group	Value	95% CI
Enlighten™ Laser and a MLA Attachment	4	± 0

12 weeks post final treatment Acne Scar Assessment Scale Score

Group	Value	95% CI
Enlighten™ Laser and a MLA Attachment	4	± 0

Adverse events — posted to ClinicalTrials.gov

Time frame: 12 weeks post-final treatment, up to 8 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Enlighten™ Laser and a MLA Attachment

Serious: 0/4 (0%)

Deaths: 0/4

Other adverse events (3 terms — click to expand)

Reaction	System	Enlighten™ Laser and a MLA…
Erythema	Skin and subcutaneous tissue disorders	—
Edema	Skin and subcutaneous tissue disorders	—
Discomfort	Skin and subcutaneous tissue disorders	—

Data from ClinicalTrials.gov NCT03430921 adverse events section.

Sponsor's own description

The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of moderate to severe acne scars.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Scarring

Currently open trials in the same condition.

NCT06448481 — Aesthetic Outcome of Intra-dermal Versus Transcutaneous Purse-string Closure · NA · recruiting
NCT06288009 — Outcomes of Running Locking Suture vs Standard Running Suture in Surgical Wounds · NA · recruiting
NCT06287866 — Pinch Grafting Versus Second Intention Wound Healing for Mohs Micrographic Surgery Defects on the Scalp · NA · recruiting
NCT05758168 — Aesthetic Outcome of Tie-over Bolster Application in Surgical Wounds · NA · recruiting
NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting

Other Cutera Inc. trials

Trials by the same sponsor.

NCT06469398 — A Post Market Device Study for the Treatment of Acne · NA · active not recruiting
NCT04695691 — A Device Study for the Treatment of Acne · NA · completed
NCT03782545 — Multi-Center Pilot Study of Cutera truSculpt Device · NA · completed
NCT03424148 — Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment · NA · completed
NCT03424161 — Multi-Center, Clinical Evaluation of the Cutera Secret RF Device · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03430921 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cutera Inc.
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing